Peptidyl-prolyl Isomerase F As a Prognostic Biomarker Associated with Immune Infiltrates and Mitophagy in Lung Adenocarcinoma

Overview

Journal Transl Lung Cancer Res

Date 2024 Jul 8

PMID 38973949

Authors

Zitong Feng

Lin Yuan

Luyuan Ma

Wenhao Yu

Fayez Kheir

Lukas Kasmann

Wolfgang M Brueckl

Kai Jin

Dingxin Wang

Yi Shen

Rongyang Li

Hui Tian

Affiliations

Soon will be listed here.

Abstract

Background: Lung adenocarcinoma (LUAD) is among the most prevalent malignancies worldwide, with unfavorable treatment outcomes. Peptidyl-prolyl isomerase F () is known to influence the malignancy traits of tumor progression by modulating the bioenergetics and mitochondrial permeability in cancer cells; however, its role in LUAD remains unclear. Our study seeks to investigate the clinical significance, tumor proliferation, and immune regulatory functions of in LUAD.

Methods: The expression of in LUAD tissues and cells was assessed using bioinformatics analysis, immunohistochemistry (IHC), and Western blotting. Survival curve analysis was conducted to examine the prognostic association between expression and LUAD. The immunomodulatory role of in LUAD was assessed through the analysis of expression and immune cell infiltration. A series of gain- and loss-of-function experiments were conducted on to investigate its biological functions in LUAD both and . The mechanisms underlying 's effects on LUAD were delineated through functional enrichment analysis and Western blotting assays.

Results: exhibited overexpression in LUAD tissues compared to normal controls. Survival curve analysis revealed that patients with LUAD exhibiting higher expression demonstrated decreased overall survival and a shorter progression-free interval. was implicated in modulating immune cell infiltration, particularly in regulating the T helper 1-T helper 2 cell balance. Functionally, was discovered to promote tumor cell proliferation and advance cell-cycle progression. Furthermore, could impede mitophagy by targeting the FOXO3a/PINK1-Parkin signaling pathway.

Conclusions: The findings of this study indicate that the prognosis-related gene may have a significant role in the regulation of LUAD cell proliferation, tumor-associated immune cell infiltration, and mitophagy, and thus may be a promising therapeutic target of LUAD.

References

Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H . Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature. 2005; 434(7033):652-8. DOI: 10.1038/nature03317. View

Wang R, Shang Y, Chen B, Xu F, Zhang J, Zhang Z . Protein disulfide isomerase blocks the interaction of LC3II-PHB2 and promotes mTOR signaling to regulate autophagy and radio/chemo-sensitivity. Cell Death Dis. 2022; 13(10):851. PMC: 9537141. DOI: 10.1038/s41419-022-05302-w. View

Ying L, Chunxia Y, Wei L . Inhibition of ovarian cancer cell growth by a novel TAK1 inhibitor LYTAK1. Cancer Chemother Pharmacol. 2015; 76(3):641-50. DOI: 10.1007/s00280-015-2822-8. View

Lu D, Liu R, Zhou Y, Zhang Z, Jiang X, Xu J . FOXO3a-dependent up-regulation of HSP90 alleviates cisplatin-induced apoptosis by activating FUNDC1-mediated mitophagy in hypoxic osteosarcoma cells. Cell Signal. 2022; 101:110500. DOI: 10.1016/j.cellsig.2022.110500. View

Gauba E, Guo L, Du H . Cyclophilin D Promotes Brain Mitochondrial F1FO ATP Synthase Dysfunction in Aging Mice. J Alzheimers Dis. 2016; 55(4):1351-1362. PMC: 5496683. DOI: 10.3233/JAD-160822. View

Ghosh J, Siegelin M, Vaira V, Faversani A, Tavecchio M, Chae Y . Adaptive mitochondrial reprogramming and resistance to PI3K therapy. J Natl Cancer Inst. 2015; 107(3). PMC: 4565533. DOI: 10.1093/jnci/dju502. View

Nagy A, Munkacsy G, Gyorffy B . Pancancer survival analysis of cancer hallmark genes. Sci Rep. 2021; 11(1):6047. PMC: 7961001. DOI: 10.1038/s41598-021-84787-5. View

Bigi A, Beltrami E, Trinei M, Stendardo M, Pelicci P, Giorgio M . Cyclophilin D counteracts P53-mediated growth arrest and promotes Ras tumorigenesis. Oncogene. 2016; 35(39):5132-43. DOI: 10.1038/onc.2016.42. View

Sentana-Lledo D, Academia E, Viray H, Rangachari D, Kobayashi S, VanderLaan P . exon 20 insertion mutations and mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates. Transl Lung Cancer Res. 2023; 12(7):1590-1610. PMC: 10413034. DOI: 10.21037/tlcr-23-98. View

10.

Riano I, Dragnev K, Phillips J . The beginning of the perioperative immunotherapy era in early-stage non-small cell lung cancer. Transl Lung Cancer Res. 2023; 12(11):2359-2365. PMC: 10713273. DOI: 10.21037/tlcr-23-470. View

11.

Satyam A, Singh P, Badjatia N, Seth A, Sharma A . A disproportion of TH1/TH2 cytokines with predominance of TH2, in urothelial carcinoma of bladder. Urol Oncol. 2009; 29(1):58-65. DOI: 10.1016/j.urolonc.2009.06.002. View

12.

Hoshino A, Mita Y, Okawa Y, Ariyoshi M, Iwai-Kanai E, Ueyama T . Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart. Nat Commun. 2013; 4:2308. DOI: 10.1038/ncomms3308. View

13.

Chen S, Li D, Yang F, Wu Z, Zhao Y, Jiang Y . Gemcitabine-induced pancreatic cancer cell death is associated with MST1/cyclophilin D mitochondrial complexation. Biochimie. 2014; 103:71-9. DOI: 10.1016/j.biochi.2014.04.004. View

14.

Beutner G, Alanzalon R, Porter Jr G . Cyclophilin D regulates the dynamic assembly of mitochondrial ATP synthase into synthasomes. Sci Rep. 2017; 7(1):14488. PMC: 5670235. DOI: 10.1038/s41598-017-14795-x. View

15.

Schubert A, Grimm S . Cyclophilin D, a component of the permeability transition-pore, is an apoptosis repressor. Cancer Res. 2004; 64(1):85-93. DOI: 10.1158/0008-5472.can-03-0476. View

16.

Prabhu V, Allen J, Dicker D, El-Deiry W . Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner. Cancer Res. 2015; 75(7):1423-32. PMC: 4537643. DOI: 10.1158/0008-5472.CAN-13-3451. View

17.

Zhang Y, Pang C, Zhang C, Wang Y, Wang P, Chen Y . HILPDA-mediated lipidomic remodelling promotes radiotherapy resistance in nasopharyngeal carcinoma by accelerating mitophagy. Cell Mol Life Sci. 2023; 80(9):242. PMC: 11072511. DOI: 10.1007/s00018-023-04891-9. View

18.

Wei Y, Xiao G, Xu H, Sun X, Shi Y, Wang F . Radiation resistance of cancer cells caused by mitochondrial dysfunction depends on SIRT3-mediated mitophagy. FEBS J. 2023; 290(14):3629-3645. DOI: 10.1111/febs.16769. View

19.

Jia J, Xia J, Liu W, Tao F, Xiao J . Cinnamtannin B-1 Inhibits the Progression of Osteosarcoma by Regulating the miR-1281/PPIF Axis. Biol Pharm Bull. 2022; 46(1):67-73. DOI: 10.1248/bpb.b22-00600. View

20.

Giang A, Raymond T, Brookes P, Bentley K, Schwarz E, OKeefe R . Mitochondrial dysfunction and permeability transition in osteosarcoma cells showing the Warburg effect. J Biol Chem. 2013; 288(46):33303-11. PMC: 3829176. DOI: 10.1074/jbc.M113.507129. View